Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM31VZT)

Drug Name

CAD-106 Drug Info

Synonyms

Amilomotide; Alzheimers disease vaccine, Cytos/Novartis; Immunodrug vaccines (Alzheimers disease), Cytos/Novartis; Beta amyloid 1-6 peptide/Qbeta virus-like particle conjugate (Alzheimer's disease), Cytos/Novartis

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2/3	[1]

Cross-matching ID

TTD Drug ID: DM31VZT

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Amyloid beta A4 protein (APP)	TTE4KHA	A4_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Amyloid beta A4 protein (APP)	DTT	APP	6.473	8.014	8.631	7.57

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Alzheimer disease

ICD Disease Classification

8A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Amyloid beta A4 protein (APP)	DTT	APP	1.60E-02	-0.07	-0.31

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT02565511) A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.
2	The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011 Jun 22;31(25):9323-31.